Related Articles
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
Case Report: Hydralazine-Induced ANCA-Associated Vasculitis
Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus. Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, serositis, myalgias and/or hepatomegaly. Features…
Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis
Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.
ACR Winter Rheumatology Symposium: Tips for ANCA Testing
How to select the correct testing method and interpret conflicting results from antineutrophil cytoplasmic antibody tests